Cervical Cancer Vaccine Suffern NY

The human papillomavirus (HPV) vaccine works for women aged 24 to 45 in Suffern who aren't already infected by HPV, the virus that has been linked to cervical cancer and other cervical diseases. That's the finding from Dr. Nubia Munoz, of the National Institute of Cancer in Bogota, Columbia, who noted that women's rising age at first marriage and increasing divorce rates have led to more widespread premarital intercourse and pairing with new sexual partners around middle age.

Local Companies

Jill S Menell
(973) 754-3230
703 Main St
Paterson, NJ
Philip J Silverman
(914) 969-1600
970 N Broadway
Yonkers, NY
MARK LEVIN, MD
(845) 406-2183
6 Gel Court
Monsey, NY
Mathew Lonberg, MD
914-362-1750
500 New Hempstead Rd Ste C
New City, NY
Hamdy A Mohtaseb, MD
973-956-9433
401 Hamburg Tpke # S#103
Wayne, NJ
Mary Ann Bonilla
(973) 754-3230
703 Main St
Paterson, NJ
Gloria A Chia
(646) 227-3813
777 N Broadway
Sleepy Hollow, NY
Norman Lester Rosen
(914) 965-2060
3333 Henry Hudson Way
Bronx, NY
SUSHIL BHARDWAJ, MD
(845) 368-8500
255 Lafayette Avenue
Suffern, NY
Edward Patrick Healey, MD
201-472-0884
58 Buttel Dr
Clifton, NJ
Data Provided by:
      

Provided By:

TUESDAY, June 2 (HealthDay News) -- The human papillomavirus (HPV) vaccine works for women aged 24 to 45 who aren't already infected by HPV, the virus that has been linked to cervical cancer and other cervical diseases.

That's the finding from Dr. Nubia Munoz, of the National Institute of Cancer in Bogota, Columbia, who noted that women's rising age at first marriage and increasing divorce rates have led to more widespread premarital intercourse and pairing with new sexual partners around middle age.

Their study included more than 3,200 women, aged 24 to 45, with no history of cervical disease or cancer or genital warts caused by HPV types 6, 11, 16 and 18. The women received either the quadrivalent HPV vaccine, which protects against the four HPV types, or a placebo at day one and months two and six of the study.

The women were followed for about 2.2 years and the researchers identified four cases of infection or disease in the vaccinated group, compared to 41 cases in the placebo group. That means the vaccine was 91 percent effective against all four virus strains.

When they looked at only HPV types 16 and 18, the researchers found four cases in the vaccine group and 23 in the placebo group, which means the vaccine was 83 percent effective against those two HPV types.

"Lower effectiveness detected in the mixed population (susceptible women and those who have already acquired HPV infection or HPV-associated disease) suggests that the public health effect of vaccinating women aged 25 to 45 years will be smaller than that recorded after vaccinating susceptible adolescents. This notion will be assessed in future cost-benefit analyses," the study authors wrote.

The findings appear online June 2 and in an upcoming print issue of The Lancet.

More information

The U.S. National Cancer Institute has more about HPV vaccines.

SOURCE: The Lancet, news release, June 1, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Fertility in Ovarian Cancer Patients Suffern NY
Saving the uterus or one ovary of a young woman with early-stage ovarian cancer can preserve her fertility without compromising her survival, a new study has found. Researchers at Columbia University College of Physicians and Surgeons found that survival rates during the first five years following the cancer diagnosis were similar between women who had one ovary or their uterus spared and those who had a hysterectomy (removal of the uterus) or both ovaries removed.
- Risks for Childhood Cancer Survivors Suffern NY
- Follow Up After Skin Cancer Suffern NY
- Delayed Prostate Cancer Therapy Suffern NY
- Breast Cancer Treatment Suffern NY
- Folic Acid Preventing Breast Cancer Suffern NY
- Colon Cancer Prevention Suffern NY
- Exercise for Prostate Cancer Suffern NY
- HPV and Cervical Cancer Suffern NY